Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (NCT07437950)
A Randomized Phase II Trial of ASTX727 With Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A MyeloMATCH Substudy
🩺 Plain-English Summary (8th-Grade Level)
This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Shorter duration venetoclax may be as effective as standard duration venetoclax when given with ASTX727 for the treatment of newly diagnosed AML.
Who can join: Review the eligibility criteria below.
Location: Illinois CancerCare-Bloomington — Bloomington, Illinois
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (25 Sites)
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- Illinois CancerCare-Eureka — Eureka, Illinois
- Illinois CancerCare-Galesburg — Galesburg, Illinois
- Illinois CancerCare-Kewanee Clinic — Kewanee, Illinois
- Illinois CancerCare-Macomb — Macomb, Illinois
- Illinois CancerCare-Ottawa Clinic — Ottawa, Illinois
- Illinois CancerCare-Pekin — Pekin, Illinois
- Illinois CancerCare-Peoria — Peoria, Illinois
- Illinois CancerCare-Peru — Peru, Illinois
- Illinois CancerCare-Princeton — Princeton, Illinois
- Springfield Clinic — Springfield, Illinois
- Springfield Memorial Hospital — Springfield, Illinois
- Illinois CancerCare - Washington — Washington, Illinois
- LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
- Trinity Health Saint Mary Mercy Livonia Hospital — Livonia, Michigan
- Trinity Health Saint Joseph Mercy Oakland Hospital — Pontiac, Michigan
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus — Ypsilanti, Michigan
- San Juan City Hospital — San Juan,
📞 Contact the Study Coordinator
Phone: (309) 243-3605
Email: andersonj@illinoiscancercare.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
- Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California
Explore by condition: All Acute Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.